Difference between revisions of "Mayan MD"
From Bioblast
| Line 19: | Line 19: | ||
|weblink=http://www.mayan-lab.com | |weblink=http://www.mayan-lab.com | ||
}} | }} | ||
== MITOEAGLE Feedback == | |||
::::''If it was possible I am very interested to participate in your action in different working groups. I am an expert in the study the role of connexins in development of diseases. We have recently started a project in order to find and design new molecules to target Cx43 and Cx26. We have access to human samples and animal models to test those molecules.We are focused in osteoarthritis (cx43), melanoma and breast cancer (Cx26).Our interest in this action is because we have found alterations in Cx43 function in the mitochondria of osteoarthritic chondrocytes. It has been demonstrated that localization of Cx43 is pivotal for mitochondrial function. In fact, mitochondrial Cx43 is essential for the ischemic preconditioning which offers potent protection against repercussion injury'' - '''[[Mayan MD |Maria D. Mayan]]''' (2016). | |||
{{Labelingperson}} | {{Labelingperson}} | ||
Revision as of 09:22, 27 May 2016
 |
News and Events |  |
 |
Working Groups | Short-Term Scientific Missions | Management Committee | Members |  |
COST Action CA15203 (2016-2021): MitoEAGLE
Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping
Mayan MD
MitoPedia topics: EAGLE
COST: Participant
| Name | Mayán María D., PhD
CellCOM Group Head |
|---|---|
| Institution | Instituto de Investigación Biomédica de A Coruña (INIBIC)
CH-Universitario de A Coruña (CHUAC - XXIAC) SERGAS |
| Address | C/ As Xubias 84, 15006 |
| City | A Coruña |
| State/Province | |
| Country | Spain |
| [email protected] | |
| Weblink | http://www.mayan-lab.com |
| O2k-Network Lab |
MITOEAGLE Feedback
- If it was possible I am very interested to participate in your action in different working groups. I am an expert in the study the role of connexins in development of diseases. We have recently started a project in order to find and design new molecules to target Cx43 and Cx26. We have access to human samples and animal models to test those molecules.We are focused in osteoarthritis (cx43), melanoma and breast cancer (Cx26).Our interest in this action is because we have found alterations in Cx43 function in the mitochondria of osteoarthritic chondrocytes. It has been demonstrated that localization of Cx43 is pivotal for mitochondrial function. In fact, mitochondrial Cx43 is essential for the ischemic preconditioning which offers potent protection against repercussion injury - Maria D. Mayan (2016).
Labels:
Publications
Add references to your publications
